Medtronic PLC $MDT Shares Sold by Ethic Inc.

Ethic Inc. decreased its position in Medtronic PLC (NYSE:MDT) by 7.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 135,412 shares of the medical technology company’s stock after selling 11,006 shares during the period. Ethic Inc.’s holdings in Medtronic were worth $12,897,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDT. 1248 Management LLC acquired a new position in shares of Medtronic in the first quarter valued at approximately $26,000. Delos Wealth Advisors LLC purchased a new stake in Medtronic in the 2nd quarter worth approximately $27,000. Twin Tree Management LP acquired a new position in Medtronic in the 1st quarter valued at $29,000. Activest Wealth Management lifted its stake in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares during the period. Finally, GFG Capital LLC acquired a new stake in shares of Medtronic during the second quarter worth $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Down 0.8%

NYSE MDT opened at $96.52 on Monday. The firm has a market capitalization of $123.74 billion, a price-to-earnings ratio of 26.02, a PEG ratio of 2.54 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. Medtronic PLC has a one year low of $79.29 and a one year high of $106.33. The company’s 50 day moving average price is $97.54 and its 200 day moving average price is $93.80.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the business earned $1.26 earnings per share. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Analyst Ratings Changes

Several research firms recently weighed in on MDT. Royal Bank Of Canada increased their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a “buy (b)” rating on shares of Medtronic in a research report on Monday, December 15th. Morgan Stanley boosted their target price on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).